I aim to contribute to corporate strategy and technology and innovation management literatures by refining the way we think about how firms’ externally accessible resources and capabilities influence those firms’ heterogeneous boundary choices and their resulting outcomes. …Read More
Increasingly, corporations are investing in entrepreneurial firms. This trend has not been overlooked by researchers in the management literature, but the majority of research studying the effects of corporate venture capital (CVC) overwhelmingly takes the perspective of the organization with the venture capital operation. …Read More
Evidence on whether startups benefit from corporate venture capital investment is equivocal. Research suggests that the principal impediment to value creation in these relationships for startups is the complexity of the larger organization – the varying incentive structures, layers of bureaucracy and convoluted decision-making processes that limit their access to valuable resources. …Read More
Startups are increasingly turning to the incumbent firms in their industries for venture capital. However, there remain significant gaps in our understanding of how these relationships influence the way they innovate. …Read More
The translation of invention to innovation is a topic that has received significant research attention in recent times. Scholars have recognized that our understanding of the factors that shape whether and when innovative technologies arise and transform industries cannot be complete without comprehending how scientific or technological discovery evolves into commercial adoption. …Read More
Recent research by Senior Fellow Gary Dushnitsky measures the innovation success of new biotech ventures by tracking their patenting and publishing rates. He and coauthor Elisa Alvarez-Garrido find that the identity of the investor makes a big difference.…Read More
Biotech start-ups are a critical source of life-saving discoveries. What happens when VCs won’t fund them?…Read More
Entrepreneurial ventures are a key source of innovation. Nowadays, ventures are backed by a wide array of investors whose complementary asset profiles differ significantly. We therefore assert that entrepreneurial ventures can no longer be studied as a homogeneous group.…Read More
Biotech startups increasingly turn to corporate venture capital (VC) arms for funding, rather than to traditional venture capitalists. The innovation implications for these startups remain unexplored. Here, we present evidence that the shift in funding patterns is associated with a greater output of scientific publications as well as patenting.…Read More
A prominent motive for corporate venture capital (CVC) is the identification of entrepreneurial-firm acquisition opportunities. Consistent with this view, we find that one of every five startups purchased by 61 top corporate investors from 1987 through 2003 is a venture portfolio company of its acquirer.…Read More
